About US
Contact us
-
When it comes to pharma corporate branding, Biogen is onto somethingPharma may have something to learn from Biogen's ($BIIB) recent move to lop the "Idec" off its name. It's not enough to rely on big drug brands and product messaging to attract consumers--and often, i2015/5/12
-
Teva passed up an opportunity to buy Mylan target Perrigo: GlobesSo far, Perrigo hasn't seemed too keen on selling itself to generics giant Mylan ($MYL). It's rejected the U.S. drugmaker three times. But word has it that Perrigo tried to link arms with another gene2015/5/12
-
FDA staffers raise doubts over key Vertex comboAs an FDA review nears for Vertex's ($VRTX) Kalydeco-lumacaftor tandem--approval of which could help Kalydeco reach 10 times the number ofcystic fibrosispatients it currently does--the agency's staffe2015/5/11
-
'No path forward' with Teva, Mylan pledges amid warring roadshowsLate last month, Teva ($TEVA) kicked off a roadshow to meet shareholders of its buyout target, Mylan ($MYL), and find out what price it'll need to put forth to convince them to support a deal. As Myla2015/5/11
-
Pharma dealmaking boosts M&A to record-setting heights in Q1No surprise that the health industry is setting records,M&A-wise. According to PricewaterhouseCoopers, life sciences companies inked 35 deals worth $166.3 billion in Q1--more than all of 2014's tr2015/5/8
-
Tiny drugmakers top list of most profitable, but Shire and Gilead are there, tooWho are the most profitable companies in healthcare? Drug companies, with 7 out of 10 slots on a ranking by profit margin. Who are the most profitable drug companies? You might scratch your heads at a2015/5/8
-
IBM's new healthcare biz gets to work on personalized cancer treatmentsIBM ($IBM) is unleashing Watson on healthcare. After scoring a trifecta of big-name deals--with Apple ($AAPL), Medtronic ($MDT) and Johnson & Johnson ($JNJ)--the tech heavyweight's brand-new healt2015/5/7
-
Pharma hikes prices on all sorts of meds, but hit diabetes hardest: BloombergHere are more stats for the price-increase tally: Twenty-seven drug brands took 20% price increases last year, and dozens saw prices at least double over the past 5 years,Bloombergreports. Once again,2015/5/7
-
Hampton steps into GSK chairman role as discontent with Witty buildsGlaxoSmithKline's ($GSK) new chairman has his work cut out for him. The British drugmaker has sluggish sales in the U.S. and revenue growth that falls behind that of its Big Pharma rivals. It also rec2015/5/6
-
Zoetis, under pressure from activist investor Ackman, will offload 10 plants to cut costsAnimal health leader Zoetis ($ZTS) is using a move out of the Amgen ($AMGN) playbook, whacking on manufacturing to cut costs and appease an aggressive activist investor. Zoetis announced in its first-2015/5/6